Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery

Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients

The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.

Inclusion Criteria:

• Systemic performance status 0-2 according to ECOG criteria
• Patients with adequate renal function: serum Cr 1.4 mg/dL or less
• Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal
• Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)
• Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)
• Patients who voluntarily decided to participate in this study and signed a written informed consent form

Exclusion Criteria:

• Patients undergoing immediate reconstruction operation
• Patients with drug allergies to painkillers and anti-inflammatory drugs
• Patients with a physical condition that would interfere with understanding and submitting the consent form